TRIM21 and interstitial lung disease: The results of the subgroup analysis showed that there were significant associations between anti-MDA5 antibody and the risk of RP-ILD development (subgroup 1: OR = 6.262, p < 0.001; subgroup 2: OR = 5.831, p < 0.001) and between anti-Ro-52 antibody and the risk of RP-ILD development (subgroup 1: OR = 2.689, p = 0.026; subgroup 2: OR = 2.264, p < 0.001).